AtaiBeckley Inc. (NasdaqGM: ATAI)
Health Care · Pharmaceuticals · US
$7.39
-0.67% today · +53.0% 1Y
AtaiBeckley Inc. (NasdaqGM: ATAI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.74B and employs 99 people.
Over the last twelve months the share price has gained 53.0%, trading between 3.27 and 7.45.
Tweenvest scores AtaiBeckley Inc. across four factors: quality 29/100, value 66/100. Its strongest factor is value.
ATAI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.74B
- Revenue (TTM)
- $4.47M
- P/E
- —
- EPS
- -2.14
- Dividend yield
- —
- Beta (5Y)
- 1.55
- 52-week high
- $7.45
- 52-week low
- $3.27
- Avg volume (3M)
- —
- Shares outstanding
- 370.86M
- Employees
- 99
- Next earnings
- —
About AtaiBeckley Inc.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
- ISIN
- US04650F1012
- Founded
- 2018
- Listed since
- Jun 18, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.